Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Net Cash Flow (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Net Cash Flow for 16 consecutive years, with -$586201.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 334.52% year-over-year to -$586201.0, compared with a TTM value of -$3.4 million through Oct 2025, up 6.24%, and an annual FY2025 reading of -$3.4 million, up 6.24% over the prior year.
  • Net Cash Flow was -$586201.0 for Q4 2025 at Pharma-Bio Serv, down from $1.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $7.6 million in Q4 2023 and bottomed at -$7.3 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$689320.4, with a median of $247766.0 recorded in 2022.
  • The sharpest move saw Net Cash Flow tumbled 919.02% in 2021, then surged 3008.91% in 2023.
  • Year by year, Net Cash Flow stood at $1.0 million in 2021, then plummeted by 75.5% to $245575.0 in 2022, then soared by 3008.91% to $7.6 million in 2023, then crashed by 96.73% to $249957.0 in 2024, then plummeted by 334.52% to -$586201.0 in 2025.
  • Business Quant data shows Net Cash Flow for PBSV at -$586201.0 in Q4 2025, $1.9 million in Q3 2025, and -$5.3 million in Q2 2025.